

OKLAHOMA BOARD OF NURSING  
2915 North Classen Boulevard, Suite 524  
Oklahoma City, OK 73106  
405-962-1800

**CRNA Inclusionary Formulary**

**To be granted authority to select, order, obtain and administer drugs**, Certified Registered Nurse Anesthetists (CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the continuing education requirements noted in the *Rules of the Oklahoma Board of Nursing*, specifically 485:10-18-2. Pursuant to 59 O.S. § 567.3a.10 [*Oklahoma Nursing Practice Act*], a Formulary Advisory Council has been established to develop and submit to the Board recommendations for an inclusionary formulary.

The following Board-approved *CRNA Inclusionary Formulary* lists drugs that may be ordered, selected, obtained or administered during the **perioperative** and **periobstetrical** periods by CRNAs who have been granted authority by the Board to select, order, obtain, and administer drugs.

---

**4:00 Antihistamine Drugs**

4:04 First Generation Antihistamines

Diphenhydramine Hydrochloride

Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24) **[CAUTION:**

**Be aware of pediatric restrictions (Not to be administered to children under the age of two years).]**

**[CAUTION: Be aware of the FDA Boxed Warning on IV use (limit the drug's concentration and rate of administration and ensure a properly functioning intravenous line).]**

**12:00 Autonomic Drugs**

12:04 Parasympathomimetic (Cholinergic) Agents

Neostigmine Bromide

Physotigmine Salicylate\*

Pyridostigmine Bromide\*

12:08 Anticholinergic Agents

12:08.08 Antimuscarinics/antispasmodics

Atropine

Glycopyrrolate

Ipratropium Bromide

Scopolomine\*

12:12 Sympathomimetic (Adrenergic) Agents

12:12.04  $\alpha$ -Adrenergic Agents

Midodrine\*

Phenylephrine

12:12.08  $\beta$ -Adrenergic Agonists

12:12.08.04 Non-selective  $\beta$ -Adrenergic Agonists

Isoproterenol\*

- 12:12.08.08 Selective  $\beta_1$ -Adrenergic Agonists
  - Dobutamine
  - Dopamine
- 12:12.08.12 Selective  $\beta_2$ -Adrenergic Agonists
  - Albuterol/Levalbuterol
  - Formoterol
  - Indacaterol
  - Metaproterenol\*
  - Salmeterol
  - Terbutaline Sulfate
- 12:12.12  $\alpha$ - and  $\beta$ -Adrenergic Agonists
  - Ephedrine
  - Epinephrine
  - Metaraminol\*
  - Norepinephrine
  - Pseudoephedrine
- 12:16 Sympatholytic (Adrenergic Blocking) Agents
  - 12:16.04  $\alpha$ -Adrenergic Blocking Agents
    - 12:16.04.04 Non-selective  $\alpha$ -Adrenergic Blocking Agents
      - Phentolamine
- 12:20 Skeletal Muscle Relaxants (all intravenous future new drugs approved)
  - 12:20.04 Centrally Acting Skeletal Muscle Relaxants
    - Carisoprodol\*
    - Cyclobenzaprine
    - Metaxalone\*
    - Methocarbamol\*
    - Tizanidine
  - 12:20.08 Direct-acting Skeletal Muscle Relaxants
    - Dantrolene Sodium
  - 12:20.12 GABA-derivative Skeletal Muscle Relaxants
    - Baclofen
  - 12:20.20 Neuromuscular Blocking Agents
    - Atracurium Besylate\*
    - Cisatracurium
    - Pancuronium Bromide\*
    - Rocuronium Bromide
    - Succinylcholine Chloride
    - Vecuronium Bromide

**16:00 Blood Derivatives**

- Albumin Human
- Plasma Protein Fraction\*

**Blood and Blood Components (not in AHFS)**

**20:00 Blood Formation and Coagulation**

- 20:12 Antithrombotic Agents
  - 20:12.04 Anticoagulants

- 20:12.04.16 Heparins
  - Enoxaparin
  - Heparin
- 20:28 Antihemorrhagic Agents
  - 20:28.08 Antiheparin Agents
    - Protamine Sulfate\*
  - 20:28.16 Hemostatics
    - Aminocaproic Acid\*
    - Tranexamic Acid (TXA) (not in AHFS)
  - 20:28.92 Antihemorrhagic Agents, Misc.
    - Idarucizumab

## **24:00 Cardiovascular Drugs**

- 24:04 Cardiac Drugs
  - 24:04.04 Antiarrhythmic Agents
    - 24:04.04.04 Class Ia Antiarrhythmics
      - Disopyramide
      - Procainamide
      - Quinidine
    - 24:04.04.08 Class Ib Antiarrhythmics
      - Lidocaine
    - 24:04.04.20 Class III Antiarrhythmics
      - Amiodarone
    - 24:04.04.24 Class IV Antiarrhythmics
      - Adenosine
  - 24:04.08 Cardiotonic Agents
    - Digoxin
- 24:08 Hypotensive Agents
  - 24:08.16 Central  $\alpha$ -Agonists
    - Clonidine
    - Methyldopa
  - 24:08.20 Direct Vasodilators
    - Hydralazine
    - Sodium Nitroprusside
- 24:12 Vasodilating Agents
  - 24:12.08 Nitrates and Nitrites
    - Nitroglycerine
- 24:24  $\beta$ -Adrenergic Blocking Agents
  - Atenolol
  - Esmolol Hydrochloride\*
  - Labetalol
  - Metoprolol
  - Nadolol\*
  - Propranolol
- 24:28 Calcium-Channel Blocking Agents
  - 24:28.08 Dihydropyridines
    - Nicardipine\*

- Nifedipine
- 24:28.92 Calcium-Channel Blocking Agents, Miscellaneous
- Verapamil
- 24:32 Renin-Angiotensin-Aldosterone System Inhibitors
- 24:32.04 Angiotensin-Converting Enzyme Inhibitors
- Captopril
- Enalaprilat/Enalapril

**28:00 Central Nervous System Agents**

- 28:04 General Anesthetics (all in this class approved including future new drugs)
  - 28:04.04 Barbiturates
  - Methohexital\*
  - 28:04.16 Inhalation Anesthetics (not in AHFS)
  - 28:04.92 General Anesthetics, Miscellaneous
  - Etomidate
  - Ketamine\*\* (not in AHFS)
  - Fospropofol
  - Propofol
- 28:08 Analgesics and Antipyretics
  - 28:08.04 Nonsteroidal Antiinflammatory Agents
    - 28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors
    - Celecoxib
    - 28:08.04.24 Salicylates
    - Aspirin
    - 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents
    - Ibuprofen (PO or IV)
    - Indomethacin
    - Ketorolac
  - 28:08.08 Opiate Agonists (all in this class approved including future new drugs)
    - Codeine\*\*\* **[NOTE: Be aware of PEDIATRIC CAUTION, FDA Drug safety communication new Boxed Warning on use after tonsillectomy or adenoidectomy 2/20/2013]**\*\*\*
    - Fentanyl
    - Hydrocodone
    - Hydromorphone
    - Levorphanol\*
    - Meperidine
    - Morphine
    - Remifentanyl\*
    - Sufentanil Citrate
    - Tramadol
  - 28:08.12 Opiate Partial Agonists (all in this class approved including future new drugs)
    - Buprenorphine
    - Butorphanol
    - Nalbuphine\*

- 28:08.92 Analgesics and Antipyretic, Miscellaneous
  - Acetaminophen (PO or IV)
  - Sodium Thiosalicylate\*
- 28:10 Opiate Antagonists (all in this class approved including future new drugs)
  - Nalmefene\*
  - Naloxone
  - Naltrexone
- 28:12 Anticonvulsants
  - 28:12.04 Barbituates
    - Phenobarbital
  - 28:12.08 Benzodiazepines
    - Clonazepam
  - 28:12.12 Hydantoins
    - Ethotoin\*
    - Fosphenytoin
    - Phenytoin
  - 28:12.92 Anticonvulsants, Miscellaneous
    - Carbamazepine
    - Felbamate\*
    - Gabapentin
    - Lamotrigine
    - Magnesium Sulfate
    - Valproate/Divalproex
- 28:16 Psychotherapeutic Agents
  - 28:16.08 Antipsychotics
    - 28:16.08.04 Atypical Antipsychotics
    - 28:16.08.08 Butyrophenones
      - Haloperidol
    - 28:16.08.24 Phenothiazines
      - Perphenazine\*
      - Prochlorperazine
- 28:20 Anorexigenic Agents and Respiratory and CNS Stimulants
  - 28:20.32 Respiratory and CNS Stimulants
    - Caffeine/Caffeine and Sodium Benzoate
    - Doxapram\*
- 28:24 Anxiolytics, Sedatives, and Hypnotics
  - 28:24.04 Barbiturates (all in this class approved including future new drugs)
    - Phenobarbital\*
  - 28:24.08 Benzodiazepines (all in this class approved including future new drugs)
    - Alprazolam
    - Chlordiazepoxide
    - Diazepam
    - Lorazepam
    - Midazolam
    - Temazepam\*
  - 28:24.92 Anxiolytics, Sedatives, and Hypnotics, Miscellaneous
    - Dexmedetomidine\*

- Hydroxyzine
- Promethazine
- 28:36 Antiparkinsonian Agents
- 28:36.08 Anticholinergic Agents
- Benztropine Mesylate
- 28:92 Central Nervous System Agents, Miscellaneous
- Flumazenil

**36:00 Diagnostic Agents**

- 36:40 Kidney Function
- Indigo Carmine (Indigotindisulfonate)\*
- 36:56 Myasthenia Gravis
- Edrophonium Chloride\*

**40:00 Electrolytic, Caloric, and Water Balance**

- 40:08 Alkalinizing Agents
- Citrate Salts
- Sodium Bicarbonate
- Sodium Lactate\*
- 40:12 Replacement Preparations
- Calcium Salts
- Dextran 40\*
- Dextran75 (not in AHFS) **[CAUTION: Potential complication of anaphylactic reaction to Dextran 75]**
- Electrolyte Solutions\*
- Hetastarch **[CAUTION: Potential complication of anaphylactic reaction to Hetastarch in patients allergic to corn] [AVOID use with renal compromised patients]**
- Potassium Supplements
- Sodium Chloride\*
- 40:20 Caloric Agents
- Dextrose\*
- Invert Sugar\*
- 40:24 Salt and Sugar Substitutes (not in AHFS)
- 40:28 Diuretics
- 40:28.08 Loop Diuretics
- Bumetanide
- Furosemide
- 40:28.12 Osmotic Diuretics
- Mannitol
- 40:28.20 Thiazide Diuretics
- Chlorothiazide

**48:00 Respiratory Tract Agents** (all in this class approved including future new drugs)

- 48:08 Antitussives
- Benzonatate\*
- Codeine

- Dextromethorphan
- Hydrocodone
- 48:16 Expectorants
  - Guaifenesin
  - Potassium Iodide (see also 68:36.08)
- 48:24 Mucolytic Agents
  - Acetylcysteine (see also 92:12)

**52:00 Eye, Ear, Nose, and Throat (EENT) Preparations**

- 52:16 Local Anesthetics
  - Benzocaine
  - Dyclonine\*
  - Proparacaine\*
  - Tetracaine\*
- 52:32 Vasoconstrictors
  - Epinephrine\*
  - Naphazoline\*
  - Oxymetazoline\*
  - Phenylephrine\*
  - Propylhexedrine\*
  - Tetrahydrolozine\*
- 52:40 Antiglaucoma Agents
  - 52:40.12 Carbonic Anhydrase Inhibitors
    - Acetazolamide\*

**56:00 Gastrointestinal Drugs**

- 56:04 Antacids and Adsorbents
  - Aluminum Carbonate
  - Aluminum Hydroxide
  - Aluminum Phosphate
  - Antacids
  - Calcium Carbonate
  - Charcoal, Activated
  - Dihydroxyaluminum Aminoacetate
  - Dihydroxyaluminum Sodium Carbonate
  - Magaldrate
  - Magnesium Carbonate
  - Magnesium Hydroxide
  - Magnesium Oxide
  - Magnesium Trisilicate
  - Sodium Bicarbonate
- 56:22 Antiemetics
  - 56:22.08 Antihistamines
    - Dimenhydrinate
    - Meclizine
    - Prochlorperazine
    - Trimethobenzamide\*

- 56:22.20 5-HT<sub>3</sub> Receptor Antagonists
  - Dolasetron\*
  - Granisetron
  - Ondansetron
- 56:22.92 Antiemetics, Miscellaneous
  - Aprepitant/Fosaprepitant
- 56:28 Antiulcer Agents and Acid Suppressants
  - 56:28.12 Histamine H<sub>2</sub>-Antagonists
    - Cimetidine\*
    - Famotidine
    - Nizatidine\*
    - Ranitidine
  - 56:28.32 Protectants
    - Sucralfate\*
  - 56:28.36 Proton-pump Inhibitors
    - Dexlansoprazole
    - Esomeprazole
    - Lansoprazole
    - Omeprazole
    - Pantoprazole
    - Rabeprazole
- 56:32 Prokinetic Agents
  - Metoclopramide

**68:00 Hormones and Synthetic Substitutes**

- 68:04 Adrenals (all in this class approved including future new drugs)
  - Beclomethasone
  - Betamethasone\*
  - Cortisone Acetate
  - Dexamethasone
  - Fludrocortisone\*
  - Flunisolide
  - Hydrocortisone
  - Methylprednisolone
  - Prednisolone
  - Prednisone
  - Triamcinolone
- 68:20 Antidiabetic Agents
  - 68:20.08 Insulins
    - Insulin Aspart
    - Insulin Glargine
    - Insulin Human
    - Insulin, Isophane (not in AHFS)
    - Insulin Lispro
    - Insulin Zinc\*
  - 68:20.20 Sulfonylureas
    - Chlorpropamide\*
    - Glimepiride\*



- Glipizide
- Glyburide
- Tolazamide\*
- Tolbutamide\*
- 68:22 Antihypoglycemic Agents
- 68:22.12 Glycogenolytic Agents
- Glucagon
- 68:28 Pituitary
- Corticotropin
- Desmopressin
- Vasopressin
- 68:44 Renin-Angiotensin-Aldosterone System (RAAS)
- Angiotensin II (not in AHFS)

**72:00 Local Anesthetics** (all in this class approved including future new drugs)

- Articaine
- Bupivacaine
- Chlorprocaine\*
- Lidocaine
- Mepivacaine
- Prilocaine
- Procaine (not in AHFS)
- Ropivacaine (not in AHFS)
- Tetracaine

**76:00 Oxytocics**

- Carboprost Tromethamine\*
- Dinoprostone
- Ergonovine/Methergonovine
- Oxytocin
- Sodium Chloride 20% Injection
- Urea 40-50% Injection

**84:00 Skin and Mucous Membrane Agents**

- 84:04 Anti-infective
- 84:04.92 Local Anti-Infectives, Miscellaneous
- Chlorhexidine gluconate\*
- 84:08 Antipruritics and Local Anesthetics (all in this class approved including future new drugs)
- Benzocaine\*
- Dibucaine\*
- Doxepin\*
- Ethyl Chloride\*
- Phenazopyridine\*
- Pramoxine\*

**86:00 Smooth Muscle Relaxants**

86:16 Respiratory Smooth Muscle Relaxants

Aminophylline

Theophyllines

**92:00 Miscellaneous Therapeutic Agents**

92:12 Antidotes

Acetylcysteine

Methylene Blue\*

Sugammadex

**[NOTE: ACLS Algorithm medications are listed according to the classification system in the AHFS Drug Information resource.]**

**Regulatory Authority:**

59 O.S. §567.4b. C.

**Reference:**

American Hospital Formulary Service®. *AHFS Drug Information* (2018). Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD.

\*Omitted from the print version of *AHFS Drug Information* because of space limitations, as stated by the publisher. May view the AHFS Drug Information website:

<http://www.ahfsdruginformation.com>

\*\*Reference for Ketamine: <http://reference.medscape.com/drug/ketalar-ketamine-343099>

\*\*\* Reference for Codeine precautions: <http://www.fda.gov/Drugs/DrugSafety/ucm118108.htm>